

### **III. AMENDMENT TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings of claims in the application:

#### **Listing of Claims:**

Claims 1-24 (canceled)

Claim 25 (previously presented) A sustained release oral dosage form comprising:  
hydromorphone or a pharmaceutically acceptable salt thereof; and  
means for providing the mean fasting plasma concentration vs. time curve of Figure  
14 upon single administration to human subjects.

Claim 26 (previously presented) A sustained release oral dosage form comprising:  
hydromorphone or a pharmaceutically acceptable salt thereof; and  
means for providing the mean fed plasma concentration vs. time curve of Figure  
14 upon single administration to human subjects.

Claim 27 (previously presented) A sustained release oral dosage form comprising:  
hydromorphone or a pharmaceutically acceptable salt thereof; and  
means for providing the mean fasting plasma concentration vs. time curve of Figure  
15 upon single administration to human subjects.

Claim 28 (previously presented) A sustained release oral dosage form comprising:  
hydromorphone or a pharmaceutically acceptable salt thereof; and  
means for providing the mean fed plasma concentration vs. time curve of Figure  
15 upon single administration to human subjects.

- Claim 29 (previously presented) A sustained release oral dosage form comprising:  
hydromorphone or a pharmaceutically acceptable salt thereof; and  
means for providing the mean plasma concentration vs. time curve of Figure  
16 upon steady state administration to human subjects.
- Claim 30 (previously presented) A sustained release oral dosage form comprising:  
hydromorphone or a pharmaceutically acceptable salt thereof; and  
means for providing the mean fasting plasma concentration vs. time curve of Figure  
17 upon single administration to human subjects.
- Claim 31 (previously presented) A sustained release oral dosage form comprising:  
hydromorphone or a pharmaceutically acceptable salt thereof; and  
means for providing the mean fed plasma concentration vs. time curve of Figure  
17 upon single administration to human subjects.
- Claim 32 (new) The dosage form of claim 25, wherein said dosage form comprises  
hydromorphone hydrochloride.
- Claim 33 (new) The dosage form of claim 26, wherein said dosage form comprises  
hydromorphone hydrochloride.
- Claim 34 (new) The dosage form of claim 27, wherein said dosage form comprises  
hydromorphone hydrochloride.
- Claim 35 (new) The dosage form of claim 28, wherein said dosage form comprises  
hydromorphone hydrochloride.
- Claim 36 (new) The dosage form of claim 29, wherein said dosage form comprises  
hydromorphone hydrochloride.

Claim 37 (new) The dosage form of claim 30, wherein said dosage form comprises hydromorphone hydrochloride.

Claim 38 (new) The dosage form of claim 31, wherein said dosage form comprises hydromorphone hydrochloride.